| Literature DB >> 31060795 |
Robert T Dess1, Payal D Soni2, William C Jackson3, Alejandro Berlin4, Brett W Cox5, Shruti Jolly3, Jason A Efstathiou6, Felix Y Feng7, Amar U Kishan8, Bradley J Stish9, Thomas M Pisansky9, Daniel E Spratt3.
Abstract
Interstitial brachytherapy is one of several curative therapeutic options for the treatment of localized prostate cancer. In this review, we summarize all available randomized data to support the optimal use of prostate brachytherapy. Evidence from completed randomized controlled trials is the focus of this review with a presentation also of important ongoing trials. Gaps in knowledge are identified where future investigation may be fruitful with intent to inspire well-designed prospective studies with standardized treatment that focuses on improving oncological outcomes, reducing morbidity, or maintaining quality of life.Entities:
Keywords: Brachytherapy; Combination therapy; HDR; LDR; Prostate cancer
Mesh:
Year: 2019 PMID: 31060795 DOI: 10.1016/j.urolonc.2019.04.009
Source DB: PubMed Journal: Urol Oncol ISSN: 1078-1439 Impact factor: 3.498